Search - tctmd.com

Displaying 21 - 40 of 159

Sort: Relevancy | Date

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

News Daily News

Transradial PCI May Attenuate Bivalirudin Benefits

Todd Neale

October 05, 2015

News Industry News

Drug Shortage Update: Eptifibatide Injection

September 23, 2015

News Daily News

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

L.A. McKeown

September 21, 2015

News Industry News

Medicure Announces Filing of sNDA for New AGGRASTAT® Indication

September 10, 2015

News Conference News ESC 2015

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Yael L. Maxwell

September 02, 2015

News Conference News ESC 2015

Prehospital Administration of Ticagrelor Cuts Early Ischemic Events in STEMI Patients

L.A. McKeown

September 01, 2015

News Daily News

Registry Study Suggests Absorb BVS Matches DES in Diabetic All-Comers

August 27, 2015

News Daily News

Staged PCI May Lower Mortality in STEMI Patients With Multivessel Disease

L.A. McKeown

August 12, 2015

News Daily News

Triple Therapy Yields No Thrombotic Benefit, More Bleeding in Older PCI Patients With A-fib

August 04, 2015

News Industry News

Eagle Pharmaceuticals’ RTU Bivalirudin NDA Accepted for Filing

July 23, 2015

News Industry News

Cardiome Submits Supplemental New Drug Submission (sNDS) For AGGRASTAT To Health Canada

July 22, 2015

News Industry News

Hospira Announces U.S. Launch of Generic Bivalirudin for Injection

July 16, 2015

News Industry News

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

July 09, 2015

News Daily News

FDA Approval of Cangrelor Expands Antiplatelet Options for PCI

Todd Neale

June 29, 2015

News Daily News

Bivalirudin Plus GPI Cuts Bleeding, Mortality in Heart Failure Patients Undergoing PCI

June 09, 2015

News Daily News

FDA Panel Backs Cangrelor for Use in PCI

Todd Neale

April 29, 2015

News Daily News

Activated Clotting Time May Predict Ischemic Events in PCI Patients on Heparin Alone

L.A. McKeown

April 28, 2015

News Daily News

BRIGHT Published: Prolonged Bivalirudin Reduces Bleeding, Tames Early Stent Thrombosis in Primary PCI

April 03, 2015

Advertisement

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

Transradial PCI May Attenuate Bivalirudin Benefits

Drug Shortage Update: Eptifibatide Injection

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

Medicure Announces Filing of sNDA for New AGGRASTAT® Indication

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Prehospital Administration of Ticagrelor Cuts Early Ischemic Events in STEMI Patients

Registry Study Suggests Absorb BVS Matches DES in Diabetic All-Comers

Staged PCI May Lower Mortality in STEMI Patients With Multivessel Disease

Triple Therapy Yields No Thrombotic Benefit, More Bleeding in Older PCI Patients With A-fib

Eagle Pharmaceuticals’ RTU Bivalirudin NDA Accepted for Filing

Cardiome Submits Supplemental New Drug Submission (sNDS) For AGGRASTAT To Health Canada

Hospira Announces U.S. Launch of Generic Bivalirudin for Injection

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

FDA Approval of Cangrelor Expands Antiplatelet Options for PCI

Bivalirudin Plus GPI Cuts Bleeding, Mortality in Heart Failure Patients Undergoing PCI

FDA Panel Backs Cangrelor for Use in PCI

Activated Clotting Time May Predict Ischemic Events in PCI Patients on Heparin Alone

BRIGHT Published: Prolonged Bivalirudin Reduces Bleeding, Tames Early Stent Thrombosis in Primary PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content